(University of Liege) Researchers have revealed that malignant melanoma can reprogram their protein synthesis machinery and become addicted to a new family of enzymes that modify transfer RNAs during acquired resistance. The inhibition of these molecules synergies with targeted therapies to produce a strong anti-tumoral effect. These new findings will be key in the development of improved diagnostic tools and melanoma treatment.
